Spots Global Cancer Trial Database for Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
Official Title: A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
Study ID: NCT05150457
Conditions
Interventions
Study Description
Brief Summary: The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
St George Private Hospital, Kogarah, New South Wales, Australia
Pindara Private Hospital, Benowa, Queensland, Australia
St. Vincents Hospital Melbourne, Fitzroy, Victoria, Australia
Contact Details
Name: Josh Xiao, PhD
Affiliation: Binacea Pharma, Inc.
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
